Global News Hubb
Advertisement Banner
  • Home
  • Politics
  • Finance
  • Technology
  • Contact
No Result
View All Result
  • Home
  • Politics
  • Finance
  • Technology
  • Contact
No Result
View All Result
Wellnessnewshubb
No Result
View All Result
Home Politics

STAT+: In bid to beat Bristol Myers, Takeda buys Nimbus’ anti-inflammatory drug for $4 billion

admin by admin
December 13, 2022
in Politics



Takeda Pharmaceuticals said Tuesday it will spend $4 billion and offer another $2 billion in milestones for an experimental anti-inflammatory pill from Nimbus Therapeutics, the largest deal yet for a new target that has already yielded one approved drug and sparked multiple startups.

Takeda will acquire a molecule that blocks TYK2, a signaling protein that affects how cells respond to common inflammatory molecules in the blood. Over the last few years, drugmakers have honed in on it as a new way to tamp down the inflammation that contributes to various autoimmune diseases.

Continue to STAT+ to read the full story…



Source link

Previous Post

ICICI Bank raises Rs 5,000 crore through bonds to fund business growth

Next Post

US charges FTX’s Bankman-Fried with fraud | Crypto News

Next Post

US charges FTX’s Bankman-Fried with fraud | Crypto News

Recommended

Brain implants that turn thoughts to speech closer to reality

3 months ago

Past eight years warmest on record, UN report warns | Climate News

3 months ago

© 2022 Global News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • Politics
  • Finance
  • Technology
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • Politics
  • Finance
  • Technology
  • Contact

© 2022 Global News Hubb All rights reserved.